Medostatin

Lovastatin, the active ingredient in Medostatin, is a HMG‑CoA reductase inhibitor presented as a tablet for oral use. It treats hypercholesterolemia and related lipid disorders in adults. GNH USA supplies Medostatin as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lovastatin is indicated for disorders of lipid metabolism and cardiovascular risk reduction.

- Hypercholesterolemia: lowers low‑density lipoprotein (LDL) cholesterol levels. - Primary hyperlipidemia: reduces total cholesterol and triglycerides. - Prevention of cardiovascular events in at‑risk patients: helps decrease the risk of heart attack and stroke.

Lovastatin may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Gastrointestinal discomfort: including nausea, abdominal pain, or constipation. - Muscle pain or weakness: myalgia without significant CK elevation. - Elevated liver enzymes: transient increases in ALT/AST. - Dizziness: occasional light‑headedness. - Rash: mild skin irritation or erythema.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with risk of renal failure. - Severe liver injury: marked hepatitis or hepatic failure. - Allergic reactions: including angioedema or anaphylaxis. - Myopathy with elevated CK: muscle toxicity requiring discontinuation. - Pancreatitis: acute inflammation of the pancreas. - Severe skin reactions: such as Stevens‑Johnson syndrome.

Before initiating therapy, clinicians should evaluate several safety considerations.

- Assess liver function: obtain baseline hepatic enzymes and monitor periodically. - Monitor muscle symptoms: advise patients to report unexplained muscle pain or weakness. - Review concomitant medications: avoid strong CYP3A4 inhibitors that raise lovastatin levels. - Consider dose adjustment in renal impairment: use caution in severe renal dysfunction. - Pregnancy and lactation: use only if benefits outweigh potential risks, as safety is not established. - Store at ambient temperature: keep below 25 °C, retain original packaging, and protect from moisture.

Lovastatin interacts with several drug classes that can alter its exposure or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): may increase lovastatin levels and risk of toxicity. - Gemfibrozil: can markedly increase risk of rhabdomyolysis. - HIV protease inhibitors (e.g., ritonavir): potentiate lovastatin exposure.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect; monitor INR closely. - Cyclosporine: may increase lovastatin concentrations; watch liver enzymes. - Antacids containing aluminum or magnesium: may reduce absorption; separate dosing by at least 2 hours.